Literature DB >> 16470083

Aldosterone--a hormone of cardiovascular adaptation and maladaptation.

Theodore L Goodfriend1.   

Abstract

Aldosterone stimulates reabsorption of sodium, sustaining blood volume and pressure in the face of salt deprivation or extracellular fluid depletion. The steroid also stimulates excretion of potassium, protecting extracellular fluid from excessive levels of that ion. These two actions are relatively rapid and clearly adaptive when appropriately initiated and terminated, but maladaptive when prolonged or excessive, causing hypertension and electrolyte imbalance. Aldosterone and other mineralocorticoids exert slower, direct effects on cells in the heart, kidneys, and vessels, leading to hypertrophy, fibrosis, and dysfunction contributing to degenerative cardiovascular diseases. The maladaptive actions of aldosterone are exacerbated by sodium chloride, angiotensin, endothelin, and certain growth factors. Damage can be minimized by antagonists of aldosterone receptors, inhibitors of the renin system, depletion of salt, and repletion of potassium and magnesium. Specific inhibitors of fibrosis and hypertrophy, and more effective inhibitors of the renin system should be useful in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470083      PMCID: PMC8109360          DOI: 10.1111/j.1524-6175.2006.05110.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  12 in total

Review 1.  Nontraditional aspects of aldosterone physiology.

Authors:  C Ngarmukos; R J Grekin
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-12       Impact factor: 4.310

Review 2.  New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.

Authors:  John W Funder
Journal:  Am Heart J       Date:  2002-11       Impact factor: 4.749

3.  Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension.

Authors:  A Tanabe; M Naruse; K Naruse; M Hase; T Yoshimoto; M Tanaka; T Seki; R Demura; H Demura
Journal:  Hypertens Res       Date:  1997-06       Impact factor: 3.872

4.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

Review 5.  Aldosterone blockade in patients with systolic left ventricular dysfunction.

Authors:  Bertram Pitt
Journal:  Circulation       Date:  2003-10-14       Impact factor: 29.690

Review 6.  A quick glance at rapid aldosterone action.

Authors:  Ralf Lösel; Armin Schultz; Martin Wehling
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

7.  Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.

Authors:  N J Brown; K S Kim; Y Q Chen; L S Blevins; J H Nadeau; S G Meranze; D E Vaughan
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

8.  Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.

Authors:  Bertram Pitt; Nathaniel Reichek; Roland Willenbrock; Faiez Zannad; Robert A Phillips; Barbara Roniker; Jay Kleiman; Scott Krause; Daniel Burns; Gordon H Williams
Journal:  Circulation       Date:  2003-09-29       Impact factor: 29.690

9.  Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.

Authors:  Masaru Hayashi; Takayoshi Tsutamoto; Atsuyuki Wada; Takashi Tsutsui; Chitose Ishii; Keijin Ohno; Masanori Fujii; Atsushi Taniguchi; Tomokazu Hamatani; Yoshitaka Nozato; Ken Kataoka; Naoki Morigami; Masato Ohnishi; Masahiko Kinoshita; Minoru Horie
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

10.  Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy.

Authors:  Theodore L Goodfriend; David A Calhoun
Journal:  Hypertension       Date:  2004-01-19       Impact factor: 10.190

View more
  6 in total

1.  Cardiac remodeling in patients with primary aldosteronism.

Authors:  F Galetta; G Bernini; F Franzoni; A Bacca; I Fivizzani; L Tocchini; M Bernini; P Fallahi; A Antonelli; G Santoro
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

Review 2.  Obesity, sleep apnea, aldosterone, and hypertension.

Authors:  Theodore L Goodfriend
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

4.  The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice.

Authors:  Michelle L Gumz; Lisa R Stow; I Jeanette Lynch; Megan M Greenlee; Alicia Rudin; Brian D Cain; David R Weaver; Charles S Wingo
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

5.  Activation of mineralocorticoid receptor by ecdysone, an adaptogenic and anabolic ecdysteroid, promotes glomerular injury and proteinuria involving overactive GSK3β pathway signaling.

Authors:  Minglei Lu; Pei Wang; Yan Ge; Lance Dworkin; Andrew Brem; Zhangsuo Liu; Rujun Gong
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

6.  Activation of RAAS Signaling Contributes to Hypertension in Aged Hyp Mice.

Authors:  Nejla Latic; Ana Zupcic; Danny Frauenstein; Reinhold G Erben
Journal:  Biomedicines       Date:  2022-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.